Do analysts prefer HOWL or CELZ?

Werewolf Therapeutics currently has a consensus price target of $3.75, indicating a potential upside of 998.10%. Given Werewolf Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Werewolf Therapeutics is more favorable than Creative Medical Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Werewolf Therapeutics 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14 Creative Medical Technology 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is HOWL or CELZ more profitable?

Creative Medical Technology's return on equity of -88.38% beat Werewolf Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Werewolf Therapeutics N/A -208.23% -75.12% Creative Medical Technology N/A -88.38% -84.71%

Do analysts prefer QNCX or CELZ?

Quince Therapeutics presently has a consensus price target of $690.00, indicating a potential upside of 3,900.00%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Quince Therapeutics is more favorable than Creative Medical Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quince Therapeutics 2 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.20 Creative Medical Technology 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is QNCX or CELZ more profitable?

Quince Therapeutics' return on equity of 0.00% beat Creative Medical Technology's return on equity. Company Net Margins Return on Equity Return on Assets Quince Therapeutics N/A N/A -67.99% Creative Medical Technology N/A -88.38% -84.71%

Do analysts recommend CELZ or BIVI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Creative Medical Technology 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CELZ or BIVI more profitable?

Creative Medical Technology's return on equity of -88.38% beat BioVie's return on equity. Company Net Margins Return on Equity Return on Assets Creative Medical Technology N/A -88.38% -84.71% BioVie N/A -101.15% -90.18%

Do analysts recommend CELZ or CYCN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Creative Medical Technology 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Cyclerion Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate AIMD or CELZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ainos 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Creative Medical Technology 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Creative Medical Technology (CELZ) Competitors

$0.85 -0.06 (-6.34%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$0.87 +0.01 (+1.72%)

As of 05:57 AM Eastern

Compare

CELZ vs. HOWL, QNCX, BIVI, CYCN, and AIMD

Should you buy Creative Medical Technology stock or one of its competitors? MarketBeat compares Creative Medical Technology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Creative Medical Technology include Werewolf Therapeutics (HOWL), Quince Therapeutics (QNCX), BioVie (BIVI), Cyclerion Therapeutics (CYCN), and Ainos (AIMD). These companies are all part of the "pharmaceutical products" industry.

How does Creative Medical Technology compare to Werewolf Therapeutics?

Werewolf Therapeutics (NASDAQ:HOWL) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

In the previous week, Werewolf Therapeutics had 4 more articles in the media than Creative Medical Technology. MarketBeat recorded 6 mentions for Werewolf Therapeutics and 2 mentions for Creative Medical Technology. Creative Medical Technology's average media sentiment score of 0.46 beat Werewolf Therapeutics' score of 0.28 indicating that Creative Medical Technology is being referred to more favorably in the news media.

Company	Overall Sentiment
Werewolf Therapeutics	Neutral
Creative Medical Technology	Neutral

Werewolf Therapeutics has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market. Comparatively, Creative Medical Technology has a beta of 1.89, meaning that its stock price is 89% more volatile than the broader market.

64.8% of Werewolf Therapeutics shares are owned by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are owned by institutional investors. 23.6% of Werewolf Therapeutics shares are owned by company insiders. Comparatively, 1.7% of Creative Medical Technology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Creative Medical Technology's return on equity of -88.38% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-208.23%	-75.12%
Creative Medical Technology	N/A	-88.38%	-84.71%

Creative Medical Technology has lower revenue, but higher earnings than Werewolf Therapeutics. Creative Medical Technology is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	$1.88M	8.83	-$60.82M	-$1.24	N/A
Creative Medical Technology	$10K	404.94	-$5.99M	-$2.14	N/A

Werewolf Therapeutics currently has a consensus price target of $3.75, indicating a potential upside of 998.10%. Given Werewolf Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Werewolf Therapeutics is more favorable than Creative Medical Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Werewolf Therapeutics beats Creative Medical Technology on 10 of the 15 factors compared between the two stocks.

How does Creative Medical Technology compare to Quince Therapeutics?

Quince Therapeutics (NASDAQ:QNCX) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

Quince Therapeutics has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Creative Medical Technology has a beta of 1.89, meaning that its stock price is 89% more volatile than the broader market.

Quince Therapeutics' return on equity of 0.00% beat Creative Medical Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	N/A	-67.99%
Creative Medical Technology	N/A	-88.38%	-84.71%

Creative Medical Technology has higher revenue and earnings than Quince Therapeutics. Creative Medical Technology is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$212.40	N/A
Creative Medical Technology	$10K	404.94	-$5.99M	-$2.14	N/A

In the previous week, Quince Therapeutics and Quince Therapeutics both had 2 articles in the media. Quince Therapeutics' average media sentiment score of 0.72 beat Creative Medical Technology's score of 0.46 indicating that Quince Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Quince Therapeutics	Positive
Creative Medical Technology	Neutral

Quince Therapeutics presently has a consensus price target of $690.00, indicating a potential upside of 3,900.00%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Quince Therapeutics is more favorable than Creative Medical Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.20
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

30.8% of Quince Therapeutics shares are owned by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are owned by institutional investors. 7.1% of Quince Therapeutics shares are owned by company insiders. Comparatively, 1.7% of Creative Medical Technology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Quince Therapeutics beats Creative Medical Technology on 10 of the 14 factors compared between the two stocks.

How does Creative Medical Technology compare to BioVie?

Creative Medical Technology (NASDAQ:CELZ) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Creative Medical Technology has higher revenue and earnings than BioVie. BioVie is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creative Medical Technology	$10K	404.94	-$5.99M	-$2.14	N/A
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Creative Medical Technology's return on equity of -88.38% beat BioVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Creative Medical Technology	N/A	-88.38%	-84.71%
BioVie	N/A	-101.15%	-90.18%

In the previous week, Creative Medical Technology had 1 more articles in the media than BioVie. MarketBeat recorded 2 mentions for Creative Medical Technology and 1 mentions for BioVie. BioVie's average media sentiment score of 1.89 beat Creative Medical Technology's score of 0.46 indicating that BioVie is being referred to more favorably in the news media.

Company	Overall Sentiment
Creative Medical Technology	Neutral
BioVie	Very Positive

Creative Medical Technology has a beta of 1.89, meaning that its share price is 89% more volatile than the broader market. Comparatively, BioVie has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market.

1.4% of Creative Medical Technology shares are owned by institutional investors. Comparatively, 4.6% of BioVie shares are owned by institutional investors. 1.7% of Creative Medical Technology shares are owned by company insiders. Comparatively, 0.9% of BioVie shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Creative Medical Technology beats BioVie on 10 of the 12 factors compared between the two stocks.

How does Creative Medical Technology compare to Cyclerion Therapeutics?

Creative Medical Technology (NASDAQ:CELZ) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk.

1.4% of Creative Medical Technology shares are owned by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are owned by institutional investors. 1.7% of Creative Medical Technology shares are owned by insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Creative Medical Technology has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. Cyclerion Therapeutics' return on equity of -62.10% beat Creative Medical Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Creative Medical Technology	N/A	-88.38%	-84.71%
Cyclerion Therapeutics	-170.11%	-62.10%	-55.14%

Creative Medical Technology has a beta of 1.89, suggesting that its share price is 89% more volatile than the broader market. Comparatively, Cyclerion Therapeutics has a beta of 1.74, suggesting that its share price is 74% more volatile than the broader market.

In the previous week, Creative Medical Technology had 1 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 2 mentions for Creative Medical Technology and 1 mentions for Cyclerion Therapeutics. Cyclerion Therapeutics' average media sentiment score of 1.87 beat Creative Medical Technology's score of 0.46 indicating that Cyclerion Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Creative Medical Technology	Neutral
Cyclerion Therapeutics	Very Positive

Cyclerion Therapeutics has higher revenue and earnings than Creative Medical Technology. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creative Medical Technology	$10K	404.94	-$5.99M	-$2.14	N/A
Cyclerion Therapeutics	$2.07M	7.99	-$3.53M	-$1.36	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Cyclerion Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Cyclerion Therapeutics beats Creative Medical Technology on 8 of the 14 factors compared between the two stocks.

How does Creative Medical Technology compare to Ainos?

Ainos (NASDAQ:AIMD) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

Creative Medical Technology has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Creative Medical Technology's return on equity of -88.38% beat Ainos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ainos	-11,912.10%	-160.55%	-62.29%
Creative Medical Technology	N/A	-88.38%	-84.71%

Ainos has a beta of 2.43, meaning that its stock price is 143% more volatile than the broader market. Comparatively, Creative Medical Technology has a beta of 1.89, meaning that its stock price is 89% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

1.4% of Creative Medical Technology shares are held by institutional investors. 9.8% of Ainos shares are held by company insiders. Comparatively, 1.7% of Creative Medical Technology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Creative Medical Technology has lower revenue, but higher earnings than Ainos. Ainos is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$120K	134.90	-$14.77M	-$2.89	N/A
Creative Medical Technology	$10K	404.94	-$5.99M	-$2.14	N/A

In the previous week, Creative Medical Technology had 1 more articles in the media than Ainos. MarketBeat recorded 2 mentions for Creative Medical Technology and 1 mentions for Ainos. Ainos' average media sentiment score of 1.89 beat Creative Medical Technology's score of 0.46 indicating that Ainos is being referred to more favorably in the media.

Company	Overall Sentiment
Ainos	Very Positive
Creative Medical Technology	Neutral

Summary

Creative Medical Technology beats Ainos on 9 of the 14 factors compared between the two stocks.

Get Creative Medical Technology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CELZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CELZ vs. The Competition

Export

Metric	Creative Medical Technology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.32M	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-0.40	20.85	27.11	24.26
Price / Sales	404.94	314.01	589.96	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	0.42	8.49	10.74	6.29
Net Income	-$5.99M	$23.83M	$3.58B	$330.66M
7 Day Performance	-21.62%	-3.56%	-2.11%	-1.35%
1 Month Performance	-60.81%	6.31%	3.27%	-0.64%
1 Year Performance	-67.64%	48.30%	26.31%	19.08%

Creative Medical Technology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CELZ Creative Medical Technology	0.5664 of 5 stars	$0.85 -6.3%	N/A	-70.6%	$4.32M	$10K	N/A	5	Short Interest Increase
HOWL Werewolf Therapeutics	3.672 of 5 stars	$0.36 -0.5%	$3.75 +947.5%	-71.3%	$17.40M	$1.88M	N/A	40
QNCX Quince Therapeutics	2.6441 of 5 stars	$17.34 +0.5%	$690.00 +3,879.2%	-95.3%	$16.99M	N/A	N/A	60
BIVI BioVie	0.4823 of 5 stars	$2.22 +2.0%	N/A	-77.0%	$16.56M	N/A	N/A	10	Positive News
CYCN Cyclerion Therapeutics	0.972 of 5 stars	$3.80 +9.5%	N/A	+4.9%	$16.45M	$1.99M	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CELZ) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Creative Medical Technology (CELZ) Competitors

CELZ vs. HOWL, QNCX, BIVI, CYCN, and AIMD

How does Creative Medical Technology compare to Werewolf Therapeutics?

Summary

How does Creative Medical Technology compare to Quince Therapeutics?

Summary

How does Creative Medical Technology compare to BioVie?

Summary

How does Creative Medical Technology compare to Cyclerion Therapeutics?

Summary

How does Creative Medical Technology compare to Ainos?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELZ vs. The Competition

Creative Medical Technology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Creative Medical Technology (CELZ) Competitors

CELZ vs. HOWL, QNCX, BIVI, CYCN, and AIMD

How does Creative Medical Technology compare to Werewolf Therapeutics?

Does the media refer more to HOWL or CELZ?

Which has more volatility & risk, HOWL or CELZ?

Do insiders & institutionals have more ownership in HOWL or CELZ?

Is HOWL or CELZ more profitable?

Which has better earnings & valuation, HOWL or CELZ?

Do analysts prefer HOWL or CELZ?

Summary

How does Creative Medical Technology compare to Quince Therapeutics?

Which has more volatility & risk, QNCX or CELZ?

Is QNCX or CELZ more profitable?

Which has better earnings and valuation, QNCX or CELZ?

Does the media refer more to QNCX or CELZ?

Do analysts prefer QNCX or CELZ?

Do insiders and institutionals believe in QNCX or CELZ?

Summary

How does Creative Medical Technology compare to BioVie?

Which has better valuation & earnings, CELZ or BIVI?

Do analysts recommend CELZ or BIVI?

Is CELZ or BIVI more profitable?

Does the media favor CELZ or BIVI?

Which has more volatility and risk, CELZ or BIVI?

Do insiders and institutionals hold more shares of CELZ or BIVI?

Summary

How does Creative Medical Technology compare to Cyclerion Therapeutics?

Do institutionals and insiders have more ownership in CELZ or CYCN?

Is CELZ or CYCN more profitable?

Which has more risk and volatility, CELZ or CYCN?

Does the media prefer CELZ or CYCN?

Which has better valuation and earnings, CELZ or CYCN?

Do analysts recommend CELZ or CYCN?

Summary

How does Creative Medical Technology compare to Ainos?

Is AIMD or CELZ more profitable?

Which has more volatility & risk, AIMD or CELZ?

Do analysts rate AIMD or CELZ?

Do insiders and institutionals believe in AIMD or CELZ?

Which has better valuation and earnings, AIMD or CELZ?

Does the media refer more to AIMD or CELZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELZ vs. The Competition

Creative Medical Technology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools